Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

Abstract

Highlights-Age, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.-Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.-Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

“…Patients with cancer are at risk of severe COVID-19 disease due to immunosuppression caused by cancer and/or cancer therapies ( Ehmsen et al., 2021b ; Tian et al., 2020 ). We and others have characterized the anti-SARS-CoV-2 immune response after two doses of COVID-19 mRNA vaccines in patients with solid and hematologic cancers and observed insufficient responses in a substantial portion ( Ehmsen et al., 2021a ; Gounant et al., 2022 ; Herishanu et al., 2022 ).…”

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

“…Patients with solid and hematologic cancer are more vulnerable to SARS-CoV-2 infection and have poorer prognoses of COVID-19 because of their general health status, immunosuppression caused by cancer itself, and/or cancer therapies (Bakouny et al, 2020, Verma et al, 2016, Ewertz et al, 2016, Ehmsen et al, 2021. COVID-19 vaccination induces both antibody and T cell immune responses, and both mRNA vaccines, BNT162b2 (Pfizer/ BioNTech) and mRNA-1273 (Moderna), are efficacious in healthy individuals in preventing COVID-19 illness, including severe disease (Baden et al, 2021, Mulligan et al, 2020.…”

COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey

“…29 This suggests that those with cancer are at an increased risk of contracting COVID-19, and experience higher morbidity and mortality due to both the disease and treatment-induced immunosuppression. [30][31][32][33][34] Second, several respondents raised concerns regarding blood clotting as a side effect of the COVID-19 vaccines. This is noteworthy because cancer is an independent risk factor for developing venous thromboembolism (VTE), and cancer-associated VTE is a leading cause of death for cancer patients, after mortality from cancer itself.…”

“…BMT patients experience additional risks due to their post-transplant immunodeficiency, necessitating a revaccination program for vaccine-preventable diseases. 28,33 Additionally, there were a small number of respondents who identified perceived futility of the vaccine, due to their prognosis. Although this may be appropriate for some patients, it requires in-depth discussions with their treating team regarding the vaccine risks and benefits at the end of life.…”